jRCT2031230572进行中（未招募）不适用
Phase III clinical evaluation of WBCRRD and SPB-KT in patients receiving continuous blood purification therapy (CBP)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 344
- 主要终点
- serum potassium level
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
入选标准
- •Written informed consent from patients or legal representative if patients lack of ability to consent.
- •Over 20 years of age at the time of acquiring consent.
- •Indications: Fluid overload, Metabolic acidosis, Urine output, Electrolytes disturbance, Intoxication, Cytokine abnormal, Severe pancreatitis acute, Hepatitis fulminant or Postoperative hepatic failure.
排除标准
- •Patients who find it difficult to receive treatment under the conditions specified in the study protocol.
- •Patients who are pregnant at the time of consent for this study.
- •Patients participating in other clinical studies at the time of consent for this study.
- •Patients judged to be inadequate for this study by the investigators .
结局指标
主要结局
serum potassium level
corrected or maintained within the target control range
serum sodium level
corrected or maintained within the target control range
次要结局
未报告次要终点
研究者
相似试验
尚未招募
3 期
Phase III clinical evaluation of WBCRRD and SPB-KT in patients receiving continuous blood purification therapy (CBP)JPRN-jRCT2031230572Kinoshita Kaori344
招募中
3 期
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerEndometrial CancerNCT06340568BioNTech SE480
进行中（未招募）
3 期
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT06448312Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.406
招募中
3 期
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerMetastatic Breast CancerNCT06081959Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.376
招募中
3 期
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination TherapyEssential HypertensionType 2 Diabetes MellitusNCT06220773Boryung Pharmaceutical Co., Ltd276